複合語候補ITC105

複合語スコア
parkinson disease4873.9532875902
motor symptoms274.92855969454
diagnosis of parkinson disease131.1076379839
nonmotor symptoms117.09629619592
advanced parkinson disease92.360517132268
dopamine agonists89.363274830466
motor symptoms of parkinson78.553707474711
deep-brain stimulation74.59684088845
movement disorder society71.500218606488
motor fluctuations63.689520441348
management of parkinson disease56.006132917313
early parkinson disease48.074220598332
symptoms of parkinson disease44.183475729254
parkinson disease psychosis43.793122353099
motor symptoms of parkinson disease40.926595225105
diagnostic criteria40.204427506014
international parkinson40.165107725478
mov disord38.875307273543
advanced disease37.177109557799
dopaminergic medications36.85007236267
h time32.967457529573
controlled trial32.76486247049
disease progression30.122360469268
red flags30.084824744691
nonmotor symptoms of parkinson disease29.862232570191
family history of parkinson disease29.129990989197
dopamine therapy28.460498941515
behavior disorder27.906971808138
treatment of parkinson disease26.475911363772
quality of life25.226892457611
causes of parkinson disease25.065305441736
clinical diagnosis of parkinson disease24.651882389253
early symptoms of parkinson disease23.834767078921
essential tremor23.354562846086
symptoms of parkinsonism23.280814202913
core motor symptoms22.953728061385
mao-b inhibitors22.133638394006
american academy of neurology21.955834260138
health care21.534253083821
mild parkinson disease21.414630753325
vascular disease21.299725353165
motor complications21.229840147116
cause of parkinson disease20.871458184133
parkinson disease medicines20.246777850204
clinical diagnosis of parkinson19.980023098479
urine storage symptoms19.946814328438
et al19.798989873223
parkinson disease exclusion criteria19.422733651409
parkinson risk18.934013359849
medical therapy18.914832180063
rest tremor18.896333544557
movement disorder society task force18.334321806849
drug therapy18.18463954209
alzheimer disease17.910862695365
pathologic progression of parkinson disease17.612331327197
pathogenesis of parkinson disease17.37931212307
suspected parkinson disease17.37931212307
gastrointestinal symptoms17.144642578193
quality standards subcommittee16.754274167162
nonmotor features of parkinson16.720012830768
early parkinson fs disease16.607407763625
non-motor symptoms of parkinson16.586227650737
management of motor symptoms16.474967959271
disease patients16.309275921902
advanced parkinson fs disease16.11424380966
many features of parkinson disease15.786666764889
differential diagnosis of parkinson disease15.715064154396
clinical parkinsonism15.640401453375
progression of motor symptoms15.470883348849
parkinson study group15.137044729979
early motor complications14.996704033586
formal diagnosis of parkinson disease14.938422933029
orthostatic hypotension14.400822974714
common neurodegenerative disorder14.005686295698
evidence-based medicine review13.830348602001
new onset parkinson disease13.321779770767
motor system disorder13.055352029391
sporadic parkinson fs disease13.021607304025
specific symptoms12.688455161287
mechanisms of parkinson12.661937868693
movement-disorder neurologist12.585385134583
adjunct therapy12.485374350864
curr opin neurol12.446568035622
n engl j med12.442410160626
olfactory dysfunction12.354362477551
primary outcome12.247448713916
seppi k12.145481106843
clinical practice12.055173868372
other side effects11.975180662096
prevalence of parkinson11.783260906255
many patients11.695646941582
physical therapy11.618950038622
disease psychosis11.444022210305
supportive criteria11.420262287518
lancet neurol11.337800126734
autonomic dysfunction11.018921819719
braak h10.767126541911
care excellence10.669676460234
disease subcommittee10.649862676582
unified parkinson10.647378163949
direct pathologic effects of parkinson disease10.63546486221
impulse control disorder10.305782432253
emergence of motor symptoms10.224723453215
recurrence of motor symptoms10.224723453215
ongoing motor symptoms10.224723453215
intrusion of motor symptoms10.224723453215
delayed greemergent h tremor of parkinson disease9.8023335195667
prevalence of parkinson disease increases9.7648279134894
evidence-based review of management of motor symptoms9.7393028255346
disease course9.6232372527296
evidence of efficacy9.3905074804397
hauser ra9.3613892772829
facial expression9.3613892772829
lang ae9.3613892772829
progressive motor9.2767515810116
common adverse effect9.2393419304495
nat rev neurol9.1088741075542
dopamine transporter8.9720926873273
fox sh8.9442719099992
lack of benefit8.7388518907318
j neurol8.732101131047
volkmann j8.6007539225133
clinical history8.568349862833
physical examination8.4519397417838
atypical parkinsonism8.3648922729551
premotor symptoms8.3494730511412
common symptoms8.3494730511412
adequate control of motor symptoms8.3150990581531
cognitive impairment8.3026954513854
balance symptoms8.1072009288422
hard-to-control disease8.0921457089563
wilson disease8.0921457089563
tremor-predominant disease8.0921457089563
disease duration8.0921457089563
motor disability8.0655950722289
mg of l-dopa8.0310685457409
cognitive deficits7.7970979610547
other gpremotor h symptoms7.7933519146605
clinical diagnostic criteria7.7800168123931
neuropathological assessment of parkinson7.6827219664325
freezing of gait7.6673172509553
sleep disorders7.6539711303027
history of head trauma7.6517247310896
katzenschlager r7.5446005780976
mood symptoms7.5446005780976
such nonmotor symptoms7.5389716958717
motor skills7.5058819657661
history of exposure7.4833147735479
adjunct medications7.4448388728168
contralateral side7.4448388728168
core motor features7.4376249540514
rapid clinical course7.4352798091322
jenner p. non-motor features of parkinson disease7.388204267999
national institutes of health7.2494296105731
urinary symptoms7.2084342424043
significant nonmotor symptoms7.1860294058534
deep-brain stimulation group7.1718695814885
clinical trial7.1680492684314
mild cognitive impairment7.1450577591353
dopamine agonist7.1352426900163
concomitant sleep disorder7.0573495735677
arch neurol7.0340079263114
jama neurol7.0340079263114
parkinson study group precept investigators7.0152924554953
initial treatment6.9992710231612
motor pathway6.7823299831253
treatment of sleep disorders6.6412202171354
risk factor6.6195018392937
drug management6.5934915059146
mood disorder6.5777363359721
study group6.5777363359721
dose of l-dopa6.5315739309452
rapid eye movement sleep behavior disorder6.4632345829234
side effect6.4474195909412
diagnostic exclusion criteria6.4282549860643
neurologic examination6.4021717458874
new clinical diagnostic criteria6.3552561177301
medication-refractory symptoms6.3442275806434
bloem br6.3442275806434
dopamine transporter imaging6.3376633710643
cognitive decline6.3086842910598
stepwise adjustment of parkinson medications6.2955545763877
cholinesterase inhibitors6.2603383202932
side effects6.2603383202932
several motor outcomes6.2250291989976
exclusion criteria6.1919769884393
advanced deep-brain stimulation therapy6.1621435496555
functional impairment6.160140576482
exercise benefits motor6.0853816070709
cognitive side effects6.0834628357098
common gastrointestinal symptoms6.0409611796005
chaudhuri kr6
bilateral deep-brain stimulation5.9718951528454
movement disorder society evidence-based medicine committee5.9686673280936
homayoun h5.957892135529
related disorders5.9436557324017
atypical parkinsonian syndromes5.9235304387295
catechol-o-methyl transferase inhibitors5.8833655068658
immediate-release drug5.803009260803
medication side effects5.7689982812296
nontremor symptoms5.7326567532262
positive symptoms5.7326567532262
important side effect of dopamine agonists5.6574926690858
progressive neurologic disorder5.6566240480853
nonmotor complications5.6513218670805
neurogenic orthostatic hypotension5.6420260246804
medical history5.5950828130598
presynaptic dopamine5.5836291546126
adverse effects5.5663153674275
initial use of dopamine agonists5.530171462735
other gait disorders5.5131462990388
lewy body dementia5.4989185479944
ma j5.4953924101089
reversible causes5.4216120216591
medication-related motor complications5.4214586731343
uncontrolled motor complications5.4214586731343
recent-onset motor fluctuations5.4214586731343
long-term motor complications5.4214586731343
h periods5.3835632709553
new diagnostic criteria5.3778905874053
marek k5.3446902355676
kieburtz k5.3446902355676
adverse medication effects5.33433655068
late manifestation of disease progression5.2945268929646
national institute5.26429605181
stern m5.26429605181
coelho m5.26429605181
good motor function5.259195040932
restless leg syndrome5.2414827884178
addition of dopamine agonists5.1854053341415
removal of dopamine agonists5.1854053341415
subthalamic nucleus5.1800401282227
disease-modifying therapies5.1800401282227
medical management5.1436867236104
symptomatic management5.1436867236104
general neurologist5.0914597900437
disease rating scale5.0783090600187
dopamine breakdown5.0453784915223
bilateral stimulation5.0453784915223
dopamine deficiency5.0453784915223
precept study4.9979987988788
prion disorder4.9979987988788
tolerability of deep-brain stimulation therapy4.9795084648368
postural tremor4.9737947036147
dopaminergic goff h periods4.9541639996482
practice parameter4.8989794855664
isaacson s4.8989794855664
idiopathic rem sleep behavior disorder4.8955667380178
absence of nonmotor features4.8856589973663
neurologist care4.8645985581956
clinical outcomes4.8427346405845
atypical neurodegenerative parkinsonism4.839811562999
alternative diagnosis4.8205705136679
formulations of l-dopa4.7753019278348
secondary nonmotor neurodegenerative causes4.7451515679786
gwearing-off h effect4.7398963239353
neurodegenerative syndrome4.7381372205376
atypical neurodegenerative parkinsonian disorders4.7184639854049
oral immediate-release l-dopa4.7101756871628
weintraub d4.6806946386414
other medications4.6806946386414
patient information4.6806946386414
bilateral subthalamic stimulation4.6196709652247
clinical presentation4.5799756509618
dopaminergic therapies4.5590141139096
zach h4.5270190558379
reichmann h4.5270190558379
h state4.5270190558379
h period4.5270190558379
h gsluggishness4.5270190558379
bruschini h4.5270190558379
williams h4.5270190558379
moderate disease severity4.5242590318911
poor sleep4.4609134425734
long-acting dopaminergic drug4.4510182535424
medication-induced dyskinesia4.4267276788013
evidence-based review4.4267276788013
quality-of-life scores4.4267276788013
surgical interventions4.4267276788013
weiner wj4.4267276788013
pulsatile stimulation of dopamine receptors4.397983489376
breathing sleep disorders4.3594283666312
nighttime sleep disorders4.3594283666312
atypical features4.3558771746929
learned motor skills4.3030146004678
perlmutter j4.3003769612566
123i-ioflupane dopamine transporter spect4.2988861033349
nonmotor disability4.294076025711
movement-disorder specialist4.2813902858562
clinical setting4.2621475953544
number of patients4.2621475953544
absence of exclusion criteria4.2484406376281
longitudinal study4.2027992734195
double-blind study4.2027992734195
placebo-controlled study4.2027992734195
open-label study4.2027992734195
rapid eye movement4.1854601371357
globus pallidus interna4.1601676461038
injectable dopamine agonist4.1601676461038
quality-of-life score4.1195342878142
troublesome dyskinesia4.1195342878142
presence of bradykinesia4.1195342878142
alternative diagnoses4.1195342878142
differential diagnosis4.0536004644211
exclusion criteria rules4.049546885517
123i-ioflupane dopamine transporter spect imaging4.0428232170799
l-dopa doses4.0155342728704
management of bladder dysfunction3.999837223024
several years of l-dopa use3.9908790767727
okun ms. deep-brain stimulation3.9600573257325
cpn study group3.9405421141402
earlystim study group3.9405421141402
pd study group3.9405421141402
special attention3.9359793425309
brundin p3.9359793425309
urinary incontinence3.9359793425309
dopaminergic drugs3.9359793425309
poewe w3.9359793425309
timmermann l3.9359793425309
typical parkinsonian gait3.9148676411689
panicker j3.8858292384691
schill j3.8858292384691
fukasaka j3.8858292384691
ferreira j3.8858292384691
aharon-peretz j3.8858292384691
send?n j3.8858292384691
jankovic j3.8858292384691
rau j3.8858292384691
seibyl j3.8858292384691
cummings j3.8858292384691
health care professional3.8701091424451
clinical findings3.8512851068431
clinical guidelines3.8512851068431
clinical efficiency3.8512851068431
clinical relevance3.8512851068431
drug administration3.8336586254776
j neurol neurosurg psychiatry3.8321775894993
early use3.8067540958393
survival study3.7976578442319
neurol clin3.7792667089114
presence of parkinsonism3.7792667089114
vascular parkinsonism3.7792667089114
movement disorders emergencies3.7788985119798
multidisciplinary care3.7606030930864
balance therapy3.7606030930864
agonist therapy3.7606030930864
patients experience3.7511661226171
nonergot dopamine agonists ropinirole3.7472768667293
long-acting l-dopa3.7368757062242
l-dopa regimen3.7368757062242
several other pathologic conditions3.723629783182
wearing-off effects3.7224194364084
daytime hypersomnolence3.7224194364084
diagnostic tool3.7224194364084
ahlskog je3.7224194364084
united states3.7224194364084
good quality of life3.7062880231628
irregular release of dopamine3.7062880231628
hours of goff h time3.6852485896495
alternate diagnosis3.6628415014847
correct diagnosis3.6628415014847
patient fs3.6628415014847
accuracy of diagnosis3.6628415014847
patients experience fluctuations3.6529276674218
several medications3.6423205736757
immediate-release formulations3.6002057436785
early fluctuations3.6002057436785
presynaptic dopaminergic system3.5953592505049
new symptomatic therapies3.5953592505049
adverse effect profile3.5953592505049
cognitive function3.5840246342157
formulations?oral extended-release l-dopa3.5345904677365
vascular disorders3.5341188430494
irreversible adverse effects3.5254687665352
serious adverse effects3.5254687665352
recent evidence-based review3.5254687665352
other information3.4996355115806
other medicines3.4996355115806
parkinsonism relat disord3.4773390964968
typical clinical presentation3.4747117108611
intrajejunal infusion of l-dopa gel3.4708216345141
base of gait3.4641016151377
postuma rb3.4641016151377
arm swings3.4641016151377
halliday gm3.4641016151377
minneap minn3.4641016151377
kalia lv3.4641016151377
first step3.4641016151377
peripheral tissues3.4641016151377
lim sy3.4641016151377
holloway rg3.4641016151377
gparkinsonism hyperpyrexia syndrome h3.4519247197843
management advances3.4397906282504
secondary parkinsonism3.4149529703483
dream phase of sleep3.4142280776924
good sleep hygiene3.4142280776924
controlled-release l-dopa3.3766483753852
sustained-release l-dopa3.3766483753852
conversion of l-dopa3.3766483753852
dopamine-blocking medications3.3635856610149
multicenter controlled trial3.3604214537127
early premotor3.3503689588345
supportive therapy3.3437015248821
disease-modifying treatment3.3437015248821
early autonomic deficits3.3334377695972
van hilten j3.3318160522188
other conditions3.3097509196469
international continence society3.3036235909394
decreased quality of life3.3019272488946
prolongation of medication effect3.3019272488946
alternative cause of parkinsonism3.2706211157025
pathologic changes3.2531531233956
neuroprotective effect3.2237097954706
future neurol3.1779718278113
prominent tremor3.1779718278113
front neurol3.1779718278113
medication-refractory tremor3.1779718278113
gastrointestinal tract3.1622776601684
few patients3.1543421455299
detailed history3.1463462836458
thorough history3.1463462836458
controlled trial of rasagiline3.14083560495
somatic features of depression3.14083560495
emergent essential tremor3.1364581089052
dopaminergic projections3.1301691601466
stepwise progression3.1301691601466
dopaminergic blockers3.1301691601466
enteral gel therapy3.1072325059539
clinical slide set3.0956162091134
complete lack of progression3.0861636884341
andante study investigators3.0668124740328
bilateral deep brain stimulation vs3.0514051588559
proper sleep hygiene3.0417314178549
other dopamine-blocking antipsychotic agents3.0350549753166
pathologic involvement3.0274001040351
refined criteria3.0274001040351
mild depression3.0274001040351
sufficient dose3.0274001040351
mandatory criteria3.0274001040351
early manifestation3.0274001040351
exclusionary criteria3.0274001040351
mao-b inhibitors selegiline3.0261714988458
further gait deficits3.0182390421613
increased risk2.9906975624424
symptom control2.9906975624424
new mixed mao-b inhibitor2.975475652329
onset of movements2.9718278662008
passive joint movement2.9595672453546
treatment of anxiety2.9428309563827
rapid-onset gait impairment2.9416827534329
expert opin drug saf2.9278526754426
sudden worsening of parkinsonism2.913792159502
acute worsening of parkinsonism2.913792159502
wearing-off time2.9129506302439
double-blind trial2.9129506302439
memory impairment2.9129506302439
alterations of gait2.9129506302439
secondary causes2.9129506302439
medication regimen2.9129506302439
effective medication2.9129506302439
intestinal gel2.9129506302439
lang a2.9129506302439
red flags rules2.9041912218409
autonomic function2.8925076085191
physiol rev2.8925076085191
intestinal gel formulations2.8844991406148
equivalent dose of immediate-release carbidopa?l2.8777854609598
lower-body parkinsonism2.8716217110259
drug-induced parkinsonism2.8716217110259
refractory tremor2.8716217110259
symmetrical parkinsonism2.8716217110259
current symptomatic therapies2.8536385282275
effective symptomatic therapies2.8536385282275
treated patients2.8502698827718
elderly patients2.8502698827718
individual patients2.8502698827718
obstructive sleep apnea2.8429702849739
stepwise assessment2.8284271247462
further dose adjustment2.8210130123402
immediate-release carbidopa-levodopa2.8173132472613
immediate-release formulation2.8173132472613
normal functional imaging2.8172691138478
oral extended-release carbidopa?l2.7981664143395
severe fluctuations2.7831576837137
other genes2.7831576837137
other considerations2.7831576837137
vitamin d2.7831576837137
other non?l2.7831576837137
other doctors2.7831576837137
common form of psychosis2.7494592739972
clin drug investig2.7494592739972
scheduled dose2.7355647997348
early stages2.7355647997348
last dose2.7355647997348
low dose2.7355647997348
reflexive eye movements2.7322193018926
several medicines2.7232698153315
standard surgical therapy2.7144176165949
initial therapies2.7108060108295
dopa gel2.7108060108295
postural imbalance2.7108060108295
postural reflexes2.7108060108295
large subset of patients2.7098746210941
early bulbar deficits2.7052932225631
dopaminergic therapy?for example2.6960123091946
recessive disorders2.6853496142827
hypokinetic disorders2.6853496142827
repetitive movements2.6853496142827
patient fs reaction2.66716827534
rescue therapy2.6591479484725
known treatment2.6591479484725
treatment of constipation2.6591479484725
functional outcomes2.6591479484725
urinary tract2.6591479484725
nat rev neurosci2.6546748825543
medication responsiveness2.632148025905
antinausea medications2.632148025905
medication-induced complications2.632148025905
goal-directed behavior2.632148025905
orthostatic lightheadedness2.632148025905
rate of progression2.632148025905
dopa medications2.632148025905
common premotor symptom2.6207413942089
alternative causes of imbalance2.6207413942089
peak drug level2.6207413942089
medical errors?may lead2.6153209720237
complete neurologic examination2.6084654714896
nat rev dis primers2.6018209830256
physical function2.5900200641113
extended-release formulation2.5900200641113
atypical signs2.5900200641113
extended-release carbidopa-levodopa2.5900200641113
advanced stages2.5755095769014
many years2.5457298950218
health professionals2.5457298950218
normal postural reflexes2.5423029068338
increase risk2.5148668593659
imaging test2.5148668593659
medical education2.5148668593659
number of steps2.5148668593659
passive movements2.4989993994394
cerebellar dysfunction2.4989993994394
severe untreated depression2.4928828716784
environmental risk factors2.4928828716784
age-associated pathologic conditions2.4643818583473
cubo e. new2.4494897427832
presence of dementia2.4494897427832
placebo group2.4494897427832
presence of freezing2.4494897427832
neuropsychiatric complications2.4494897427832
concomitant depression2.4494897427832
daily wearing-off time2.4494897427832
schrag a2.4494897427832
antipsychotic benefit2.4494897427832
hur k2.4147364027664
chi-burris k2.4147364027664
sethi k2.4147364027664
knudsen k2.4147364027664
kochi k2.4147364027664
hasegawa k2.4147364027664
follett k2.4147364027664
selective serotonin reuptake inhibitors2.4136903820681
cochrane database syst rev2.4052058575179
koller m2.3784142300054
respiratory muscle2.3784142300054
muscle tone2.3784142300054
role of exercise2.3784142300054
hellmich m2.3784142300054
hallett m2.3784142300054
murata m2.3784142300054
stamelou m2.3784142300054
systematic review2.3784142300054
grundman m2.3784142300054
politis m2.3784142300054
detrusor muscle2.3784142300054
munneke m2.3784142300054
schootman m2.3784142300054
assessment of safety2.3784142300054
muscle weakness2.3784142300054
balance changes2.3784142300054
memory changes2.3784142300054
stacy m2.3784142300054
auffret m2.3784142300054
severe postural instability2.376176797565
several cellular mechanisms2.3672935308725
braak e. staging of brain pathology2.3521580450494
quality-of-life outcomes2.3403473193207
pyramidal tract2.3403473193207
multidisciplinary team2.3403473193207
use of apomorphine2.3403473193207
nervous system2.3403473193207
protein intake2.3403473193207
wheelchair use2.3403473193207
fluid intake2.3403473193207
normal muscle paralysis2.3299861015014
generalized slowing of movements2.3201751253057
autonomic functions2.3003266337912
available therapies2.2795070569548
one exclusion criterion2.2787044788325
del tredici k2.2677220247015
involuntary movements2.2581008643532
erectile dysfunction2.2581008643532
limb movements2.2581008643532
amplitude of movements2.2581008643532
extraocular movements2.2581008643532
mitochondrial dysfunction2.2581008643532
vestibular dysfunction2.2581008643532
direction of movements2.2581008643532
rhythm of movements2.2581008643532
prior head trauma2.2449240966188
disease-modifying drugs2.2360679774998
multiple system atrophy2.2209061548523
enough vitamin d2.2209061548523
depression scales2.2133638394006
regular exercise2.2133638394006
practice improvement2.2133638394006
fahn s2.2133638394006
hsu a2.2133638394006
finkbeiner s2.2133638394006
proven efficacy2.2133638394006
shown efficacy2.2133638394006
jette n2.2133638394006
frolkis a2.2133638394006
perez-lloret s2.2133638394006
reich s2.2133638394006
fasano a2.2133638394006
dopamine-refractory depression2.2133638394006
eberly s2.2133638394006
drapier s2.2133638394006
gnonmotor fluctuations2.2133638394006
quinn n2.2133638394006
corbett a2.2133638394006
cecere a2.2133638394006
aldakheel a2.2133638394006
levodopa adjunct2.2133638394006
choudhry a2.2133638394006
brice a2.2133638394006
overeem s2.2133638394006
kell s2.2133638394006
efficacy of safinamide2.2133638394006
lack of cost-effectiveness2.2133638394006
ziemann a2.2133638394006
device-related complications2.2133638394006
lesage s2.2133638394006
administration of botulinum toxin2.1822472719434
uniform slowness of movements2.1685638970161
several seconds2.165736770668
several situations2.165736770668
several options2.165736770668
several weeks2.165736770668
gronseth g2.1406951429281
mild unsteadiness2.1406951429281
many clinicians2.1406951429281
neuroleptic malignant syndrome2.1398263878673
u.k. national institute2.1398263878673
cortical sensory loss2.1398263878673
schrag a. psychosis2.1398263878673
multidisciplinary team of clinicians2.1169328630255
impaired attention2.1147425268811
mills r2.1147425268811
cortical signs2.1147425268811
recent advances2.1147425268811
number of persons2.1147425268811
shimazu r2.1147425268811
oakes d2.1147425268811
silver d2.1147425268811
constantinescu r2.1147425268811
aarsland d2.1147425268811
berg d2.1147425268811
savica r2.1147425268811
sakakibara r2.1147425268811
recent studies2.1147425268811
dano r2.1147425268811
van der marck ma2.1039790110173
24-hour urine copper level2.0870738306761
recent technologic advances2.0757816311124
additional pertinent information2.0757816311124
magnetic resonance imaging2.0757816311124
limited oral intake2.0757816311124
g?nier marchand d2.0757816311124
physical therapist2.0597671439071
neurobiol dis2.0597671439071
bilateral lesions2.0597671439071
placebo-controlled phase2.0597671439071
substantia nigra2.0597671439071
overactive bladder2.0597671439071
ba f2.0597671439071
poor mood2.0597671439071
bladder infection2.0597671439071
volume of speech2.0597671439071
university of pittsburgh medical center2.0565711885958
intraintestinal infusion of carbidopa?l2.0396489026555
global life expectancy2.0396489026555
barton b2
glutamate-release inhibitor2
dopamine-blocking properties2
b isoform of monoamine oxidase2
typical doses2
parkinson-related psychosis2
ravina b2
longer-acting formulations2
nalls ma2
mena ma2
neuroprotective role2
cholinesterase inhibitor pyridostigmine2
à3-adrenergic agonist2
vigorous exercise2
first-in-human assessment of prx0022
multiple doses2
unprovoked psychosis2
off balance2
anecdotal evidence2
creese b2
agid y. subthalamic neurostimulation1.9839302766304
evening fluid intake1.9786024464679
pyramidal tract sign1.9786024464679
anticholinergic agents1.9679896712654
available drugs1.9679896712654
certain medicines1.9679896712654
cerebellar signs1.9679896712654
antinausea agents1.9679896712654
cystoscopic injection of botulinum toxin1.9579730911015
progressive supranuclear palsy1.9559811771959
anticholinergic agent glycopyrrolate1.9441612972397
antiepileptic agent zonisamide1.9441612972397
olfactory deficit1.9343364202677
loddo g1.9343364202677
autoactivation deficits1.9343364202677
olfactory bulb1.9343364202677
annesi g1.9343364202677
progressive decrements1.9343364202677
mild nausea1.9343364202677
giannini g1.9343364202677
progressive aphasia1.9343364202677
progressive speeding1.9343364202677
calandra-buonaura g1.9343364202677
deuschl g1.9343364202677
akinetic rigid form1.9063685859939
patient handouts1.8612097182042
kenney c1.8612097182042
vascular parkinsonism?characteristics1.8612097182042
unintelligible speech1.8612097182042
factor sa1.8612097182042
modest benefit1.8612097182042
weight loss1.8612097182042
mg of carbidopa1.8612097182042
additional carbidopa1.8612097182042
variable expression1.8612097182042
evanoff ba1.8612097182042
few studies1.8612097182042
healthy diet1.8612097182042
rapid withdrawal1.8612097182042
psychomotor slowing1.8612097182042
speech pathologist1.8612097182042
eggers c1.8612097182042
troubling dyskinesia1.8612097182042
houman homayoun1.8612097182042
environmental factors1.8612097182042
harris c1.8612097182042
lots of water1.8612097182042
copper deposits1.8612097182042
v?rin m. pharmacological insights1.8612097182042
vos ra1.8612097182042
loss of motivation1.8612097182042
clarke c1.8612097182042
significant disability1.8612097182042
various factors1.8612097182042
ratchet-like resistance1.8612097182042
duyckaerts c1.8612097182042
zesiewicz t1.8612097182042
dr. homayoun1.8612097182042
frontotemporal dementia1.8612097182042
late-onset dementia1.8612097182042
initial monotherapy1.8612097182042
single-photon emission1.8612097182042
benefits of hypnotics1.8612097182042
dietary modification1.8612097182042
racette ba1.8612097182042
projected number of people1.8493111942973
substantia nigra pars1.8171205928321
guttman m. effectiveness1.8171205928321
positron emission tomography1.8171205928321
major dietary restriction1.8171205928321
eating lots of fiber1.8171205928321
repetitive motion fatigue1.7817974362807
lead pipe rigidity1.7817974362807
such fine-motor tasks1.7817974362807
marks wj jr1.7817974362807
called lewy bodies1.7817974362807
such structural abnormalities1.7817974362807
ipx066 advance-pd investigators1.7817974362807
short-term memory problems1.7817974362807
variety of signs1.7782794100389
close attention1.7782794100389
zago w1.7782794100389
grossardt br1.7782794100389
multidisciplinary approach1.7782794100389
krack p1.7782794100389
bulk-forming agents1.7782794100389
oertel w1.7782794100389
normal perception1.7782794100389
sambati l1.7782794100389
appropriate drugs1.7782794100389
severe dystonia1.7782794100389
cortelli p1.7782794100389
klingelhoefer l1.7782794100389
longitudinal follow-up of swedd subjects1.7692284081335
multicenter analysis of glucocerebrosidase mutations1.7692284081335
slow prion-like pattern of spread1.7692284081335
author thanks kelvin l. chou1.7411011265923
caregiver stress1.7320508075689
prominent unsteadiness1.7320508075689
large meals1.7320508075689
open-label results1.7320508075689
caregiver burden1.7320508075689
sufficient fiber1.7320508075689
nursing home placement1.6983813295649
regular bedtime routine1.6983813295649
neurourology promotion committee1.6983813295649
high-intensity resistance training1.6983813295649
faulty protein degradation1.6983813295649
unilateral presentation1.6817928305074
reliable test1.6817928305074
impaired performance1.6817928305074
impaired language1.6817928305074
multiple domains1.6817928305074
sidransky e1.6817928305074
prolonged periods1.6817928305074
neuroprotective trials1.6817928305074
pull test1.6817928305074
daytime naps1.6817928305074
corrective steps1.6817928305074
ebersbach g. nonpharmacological treatments1.6817928305074
united kingdom1.6817928305074
increased susceptibility1.6817928305074
stooped posture1.6817928305074
diet modifications1.6817928305074
absence of contraindications1.6817928305074
later stages1.6817928305074
posture holding1.6817928305074
cortical regions1.6817928305074
repetitive maneuvers1.6817928305074
intestinal absorption1.6817928305074
finazzi-agro e1.6817928305074
excessive gambling1.6817928305074
increased mortality1.6817928305074
pesticide exposure1.6817928305074
pathology of synucleinopathies1.6817928305074
gasser t1.6817928305074
additional testing1.6817928305074
improved scores1.6817928305074
urodynamic studies1.6817928305074
excessive sleepiness1.6817928305074
duda je1.6817928305074
narrow base1.6817928305074
excessive sedation1.6817928305074
tool kit1.6817928305074
pringsheim t1.6817928305074
eyal e1.6817928305074
professional organizations1.6817928305074
shortened steps1.6817928305074
anti-a-synuclein monoclonal antibody1.5874010519682
unique challenges of dyskinesias1.5874010519682
n-methyl-d-aspartate antagonist amantadine1.5874010519682
corticobasal ganglionic degeneration1.5874010519682
neutral amino acids1.5874010519682
irresistible gsleep attacks1.5874010519682
reduced stride length1.5874010519682
sleep?wake cycle disruption1.5874010519682
jansen steur en1.5874010519682
norepinephrine prodrug droxidopa1.5874010519682
low-hanging fruit of neurodegeneration1.5874010519682
agricultural occupations1.5650845800733
midbrain involvement1.5650845800733
corti o1.5650845800733
agricultural industry1.5650845800733
economic burden1.5650845800733
transdermal patch1.5650845800733
fung vs1.5650845800733
perlmutter js1.5650845800733
healthy volunteers1.5650845800733
neuropsychiatric issues1.5650845800733
dorsey er1.5650845800733
schapira ahv1.5650845800733
high-protein meals1.5650845800733
supine position1.5650845800733
y?benes jg1.5650845800733
gronseth gs1.5650845800733
nursing homes1.5650845800733
selective ¿1.5650845800733
kordower jh1.5650845800733
hormonal disturbances1.5650845800733
klostermann f1.5650845800733
bower jh1.5650845800733
mild-to-severe anxiety1.5650845800733
rotigotine patch1.5650845800733
zesiewicz ta1.5650845800733
negative results1.5650845800733
oxidative stress1.5650845800733
certain things1.5650845800733
mass lesions1.5650845800733
metabolic disturbances1.5650845800733
suchowersky o1.5650845800733
current efforts1.5650845800733
daily activities1.5650845800733
outpatient setting1.5650845800733
various strategies1.5650845800733
supine hypertension1.5650845800733
barbosa er1.5650845800733
volume of voice1.5650845800733
schapira ah1.5650845800733
major source1.5650845800733
computed tomography1.5650845800733
neurobiol aging1.5650845800733
slow pace1.5650845800733
japan zonisamide1.5650845800733
goldman jg1.5650845800733
schuepbach wm1.4142135623731
subdural hematoma1.4142135623731
disease-specific biomarkers1.4142135623731
therapeutic response1.4142135623731
parkin mutation1.4142135623731
dickson dw1.4142135623731
vries nm1.4142135623731
borm gf1.4142135623731
monogenic causation1.4142135623731
mental calculations1.4142135623731
fernandez hh1.4142135623731
nice guideline1.4142135623731
whole grains1.4142135623731
gallagher da1.4142135623731
ben-shlomo y1.4142135623731
upper extremities1.4142135623731
neurosurgical approaches1.4142135623731
second opinion1.4142135623731
ophthalmologic referral1.4142135623731
robottom bj1.4142135623731
basal ganglia1.4142135623731
u.s. food1.4142135623731
espay aj1.4142135623731
4.6 hours1.4142135623731
steeves td1.4142135623731
visual misperceptions1.4142135623731
aasly jo1.4142135623731
polyethylene glycol1.4142135623731
modified barium1.4142135623731
full spectrum1.4142135623731
formed hallucinations1.4142135623731
populous nations1.4142135623731
stowe rl1.4142135623731
iacovelli v1.4142135623731
rocca wa1.4142135623731
willis aw1.4142135623731
sullivan kl1.4142135623731
griffith sg1.4142135623731
bhatia kp1.4142135623731
nocturnal polyuria1.4142135623731
exception of quetiapine1.4142135623731
high-compression stockings1.4142135623731
heavy metals1.4142135623731
odds ratio1.4142135623731
r?b u1.4142135623731
morgan jc1.4142135623731
serum ceruloplasmin1.4142135623731
neurourol urodyn1.4142135623731
light touch1.4142135623731
4.8 hours1.4142135623731
sexual activity1.4142135623731
eszopiclone trazodone1.4142135623731
standaert dg1.4142135623731
gagnon jf1.4142135623731
miyasaki jm1.4142135623731
small vessel1.4142135623731
off-label indication1.4142135623731
hawker rj1.4142135623731
dirkx mf1.4142135623731
misfolded proteins1.4142135623731
schenk db1.4142135623731
plasma levels1.4142135623731
fink gr1.4142135623731
portable pump?have1.4142135623731
valproic acid1.4142135623731
ives nj1.4142135623731
previous version1.4142135623731
immediate reinstitution1.4142135623731
production of neurotransmitters1.4142135623731
focus of development1.4142135623731
goetz cg1.4142135623731
index finger1.4142135623731
helmich rc1.4142135623731
brandt md1.4142135623731
mason ar1.4142135623731
bie rma1.4142135623731
1-agonist midodrine1.4142135623731
martin wr1.4142135623731
potential candidates1.4142135623731
salivary glands1.4142135623731
jost wh1.4142135623731
tanner cm1.4142135623731
lozano am1.4142135623731
social goals1.4142135623731
enactment of dreams1.4142135623731
axial mobility1.4142135623731
systemic infections1.4142135623731
normal-pressure hydrocephalus1.4142135623731
korczyn ad1.4142135623731
olanow cw1.4142135623731
multistep turns1.4142135623731
biglan km1.4142135623731
incomplete penetrance1.4142135623731
evaluation of candidacy1.4142135623731
ffytche dh1.4142135623731
inspiratory stridor1.4142135623731
experimental models1.4142135623731
vegetable picker1.4142135623731
challenging cases1.4142135623731
ness dk1.4142135623731
neuronal injury1.4142135623731
montplaisir jy1.4142135623731
bertrand ja1.4142135623731
antiemetic domperidone1.4142135623731
frequent monitoring1.4142135623731
weaver fm1.4142135623731
kayser?fleischer rings1.4142135623731
personal fees1.4142135623731
recommendations of experts1.4142135623731
similar antidepressants1.4142135623731
thompson jp1.4142135623731
integrated healthcare1.4142135623731
intracytoplasmic inclusions1.4142135623731
reward processing1.4142135623731
mayo foundation1.4142135623731
stool softeners1.4142135623731
.0 b013e31822c91231
.0 b013e3181d55f241
0.4 hour1
.0 b013e318225ab661